Association between body mass index and cancer survival in a pooled analysis of 22 clinical trials

Cancer Epidemiology Biomarkers and Prevention

Volumn 26, Issue 1, 2017, Pages 21-29

  Greenlee, Heather ^a,b   Unger, Joseph M ^c,d   LeBlanc, Michael ^c,d   Ramsey, Scott ^d   Hershman, Dawn L ^a,b,e  

^a Department of Medicine   (United States)

^b Department of Medicine   (United States)

^c SWOG STATISTICAL CENTER   (United States)

^d USA   (United States)

^e NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCG VACCINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; IMATINIB; PACLITAXEL; PREDNISONE; VINCRISTINE SULFATE; VINORELBINE TARTRATE;

ACUTE MYELOID LEUKEMIA; ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; BLADDER CANCER; BODY MASS; BODY SURFACE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; COLORECTAL CANCER; CONFERENCE PAPER; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; KIDNEY CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CANCER; NON SMALL CELL LUNG CANCER; NONHODGKIN LYMPHOMA; OBESITY; OVARY CANCER; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POST TREATMENT SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; SARCOMA; SEX DIFFERENCE; ADULT; AGED; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; FACTUAL DATABASE; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; NEOPLASM; PATHOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SURVIVAL ANALYSIS; UNITED STATES;

ADULT; AGED; BODY MASS INDEX; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DATABASES, FACTUAL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS; OBESITY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; SURVIVAL ANALYSIS; UNITED STATES;

EID: 85009067836     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-15-1336     Document Type: Conference Paper

References (40)

1. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA 2014;311: 806-14.
2. Sparano JA, Wang M, Zhao F, Stearns V, Martino S, Ligibel JA, et al. Obesity at diagnosis is associated with inferior outcomes in hormone receptorpositive operable breast cancer. Cancer 2012;118:5937-46.
3. Crozier JA, Moreno-Aspitia A, Ballman KV, Dueck AC, Pockaj BA, Perez EA. Effect of body mass index on tumor characteristics and disease-free survival in patients from the HER2-positive adjuvant trastuzumab trial N9831. Cancer 2013;119:2447-54.
4. de Azambuja E, McCaskill-Stevens W, Francis P, Quinaux E, Crown JA, Vicente M, et al. The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: The experience of the BIG 02-98 trial. Breast Cancer Res Treat 2010; 119:145-53.
5. Fontanella C, Lederer B, Gade S, VanoppenM, Blohmer JU, Costa SD, et al. Impact of body mass index on neoadjuvant treatment outcome: A pooled analysis of eight prospective neoadjuvant breast cancer trials. Breast Cancer Res Treat 2015;150:127-39.
6. Wright ME, Chang S-C, Schatzkin A, Albanes D, Kipnis V, Mouw T, et al. Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer 2007;109:675-84.
7. Rodriguez C, Patel AV, Calle EE, Jacobs EJ, Chao A, Thun MJ. Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiol Biomarkers Prev 2001;10: 345-53.
8. Andersson SO, Wolk A, Bergstrom R, Adami HO, Engholm G, Englund A, et al. Body size and prostate cancer: A 20-year follow-up study among 135006 Swedish construction workers. J Natl Cancer Inst 1997;89:385-9.
9. Chiu BC-H, Gapstur SM, Greenland P, Wang R, Dyer A. Body mass index, abnormal glucose metabolism, and mortality from hematopoietic cancer. Cancer Epidemiol Biomarkers Prev 2006;15:2348-54.
10. IyengarNM, Kochhar A, Morris PG, Morris LG, Zhou XK, Ghossein RA, et al. Impact of obesity on the survival of patientswith early-stage squamous cell carcinoma of the oral tongue. Cancer 2014;120:983-91.
11. Tait S, Pacheco J, Gao F, Bumb C, EllisM, Ma C. Body mass index, diabetes, and triple-negative breast cancer prognosis. Breast Cancer Res Treat. 2014;146:189-97.
12. Kasenda B, Bass A, Koeberle D, Pestalozzi B, Borner M, Herrmann R, et al. Survival in overweight patients with advanced pancreatic carcinoma: A multicentre cohort study. BMC Cancer 2014;14:728.
13. Choi Y, Kim T-Y, Lee K-H, Han S-W, Oh D-Y, Im S-A, et al. The impact of body mass index dynamics on survival of patients with advanced pancreatic cancer receiving chemotherapy. J Pain Symptom Manage 2013;48: 13-25.
14. Zhou Y, Chlebowski R, LaMonte MJ, Bea JW, Qi L, Wallace R, et al. Body mass index, physical activity, and mortality in women diagnosed with ovarian cancer: results from the Women'sHealth Initiative. Gynecol Oncol 2014;133:4-10.
15. Pelser C, Arem H, Pfeiffer RM, Elena JW, Alfano CM, Hollenbeck AR, et al. Prediagnostic lifestyle factors and survival after colon and rectal cancer diagnosis in theNational Institutes of Health (NIH)-AARP Diet andHealth Study. Cancer 2014;120:1540-7.
16. Hayashi Y, Correa AM, Hofstetter WL, Vaporciyan AA, Rice DC, Walsh GL, et al. The influence of high body mass index on the prognosis of patients with esophageal cancer after surgery as primary therapy. Cancer 2010;116: 5619-27.
17. Brunner AM, Sadrzadeh H, Feng Y, Drapkin BJ, Ballen KK, Attar EC, et al. Association between baseline body mass index and overall survival among patients over age 60 with acute myeloid leukemia. Am J Hematol 2013;88:642-6.
18. Beason TS, Chang S-H, Sanfilippo KM, Luo S, Colditz GA, Vij R, et al. Influence of body mass index on survival in veterans with multiple myeloma. The Oncologist 2013;18:1074-9.
19. Karnell LH, Sperry SM, Anderson CM, Pagedar NA. Influence of body composition on survival in patients with head and neck cancer. HeadNeck 2014;38Suppl 1:E261-7.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
21. Cox DR.Regression models and life-Tables. J Royal Stat Soci Series B, Stat Methodol 1972;34:187-.
22. Unger JM, Barlow WE, Martin DP, Ramsey SD, Leblanc M, Etzioni R, et al. Comparison of survival outcomes among cancer patients treated in and out of clinical trials. J Natl Cancer Inst 2014;106:dju002.
23. Wu S, Liu J, Wang X, Li M, Gan Y, Tang Y. Association of obesity and overweight with overall survival in colorectal cancer patients: A meta-Analysis of 29 studies. Cancer Causes Control 2014;25:1489-502.
24. Kwan ML, Chen WY, Kroenke CH, Weltzien EK, Beasley JM, Nechuta SJ, et al. Pre-diagnosis body mass index and survival after breast cancer in the After Breast Cancer Pooling Project. Breast Cancer Res Treat 2012;132: 729-39.
25. Moller H, Roswall N, Van Hemelrijck M, Larsen SB, Cuzick J, Holmberg L, et al. Prostate cancer incidence, clinical stage and survival in relation to obesity: A prospective cohort study in Denmark. Int J Cancer 2015;136: 1940-7.
26. Smith MR. Obesity and sex steroids during gonadotropin-releasing hormone agonist treatment for prostate cancer. Clin Cancer Res 2007;13: 241-5.
27. Blauwhoff-Buskermolen S, Versteeg KS, de van der Schueren MA, den Braver NR, Berkhof J, Langius JA, et al. Loss of muscle mass during chemotherapy is predictive for poor survival of patients with metastatic colorectal cancer. J Clin Oncol 2016;34:1339-44.
28. Shachar SS, Williams GR, Muss HB, Nishijima TF. Prognostic value of sarcopenia in adults with solid tumours: A meta-Analysis and systematic review. Eur J Cancer 2016;57:58-67.
29. Gallagher D, Visser M, De Meersman RE, Sepulveda D, Baumgartner RN, Pierson RN, et al. Appendicular skeletal musclemass: effects of age, gender, and ethnicity. J Appl Physiol 1997;83:229-39.
30. Janssen I, Heymsfield SB, Wang ZM, Ross R. Skeletal muscle mass and distribution in 468 men and women aged 18-88 yr. J Appl Physiol 2000;89:81-8.
31. Flegal KM, Kit BK, Graubard BI. Body mass index categories in observational studies of weight and risk of death. Am J Epidemiol 2014;180: 288-96.
32. Flegal KM, Graubard BI, Williamson DF, Gail MH. Excess deaths associated with underweight, overweight, and obesity. JAMA 2005;293: 1861-7.
33. Kwan ML, John EM, Caan BJ, Lee VS, Bernstein L, Cheng I, et al. Obesity and mortality after breast cancer by race/ethnicity: The California Breast Cancer Survivorship Consortium. Am J Epidemiol 2014;179:95-111.
34. Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: A systematic review and meta-Analysis. JAMA 2013;309: 71-82.
35. Greenberg J. Underweight, overweight, obesity, and excess deaths. JAMA 2005;294:author reply 552-3.
36. Strickler HD, Hall C, Wylie-Rosett J, Rohan T. Underweight, overweight, obesity, and excess deaths. JAMA 2005;294:551-2; author reply 552-3.
37. Willett WC, Hu FB, Colditz GA, Manson JE. Underweight, overweight, obesity, and excess deaths. JAMA 2005;294:551; author reply 552-3.
38. Alley DE, Metter EJ, Griswold ME, Harris TB, Simonsick EM, Longo DL, et al. Changes in weight at the end of life: characterizingweight loss by time to death in a cohort study of older men.AmJ Epidemiol 2010;172:558-65.
39. American Institute for Cancer Research. Recommendations for cancer prevention; 2013 [cited 2013 May 1]. Available from: http://preventcancer. aicr.org/site/PageServer?pagename=recommendations-home.
40. Kushi LH, Doyle C, McCullough M, Rock CL, Demark-Wahnefried W, Bandera EV, et al. American Cancer Society guidelines on nutrition and physical activity for cancer prevention. CA Cancer J Clin 2012;62:30-67.